GlobeNewswire: ChemoCentryx, Inc. Contains the last 10 of 250 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:10:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/10/17/2535483/0/en/ChemoCentryx-Announces-Presentations-at-the-2022-American-Society-of-Nephrology-and-American-College-of-Rheumatology-Annual-Meetings.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings2022-10-17T12:30:00Z<![CDATA[-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR --SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.]]>https://www.globenewswire.com/news-release/2022/10/05/2528699/0/en/ChemoCentryx-Announces-Upcoming-Presentations-for-Orally-Administered-PD-L1-Inhibitor-CCX559-at-the-2022-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting2022-10-05T12:30:00Z<![CDATA[-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model --SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA.]]>https://www.globenewswire.com/news-release/2022/08/24/2503784/0/en/ChemoCentryx-Announces-TAVNEOS-avacopan-Presentations-at-Upcoming-Medical-Conferences.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences2022-08-24T12:30:00Z<![CDATA[SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN).]]>https://www.globenewswire.com/news-release/2022/08/09/2494888/0/en/ChemoCentryx-Cancels-Second-Quarter-2022-Financial-Results-Conference-Call.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call2022-08-09T12:30:00Z<![CDATA[SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx.]]>https://www.globenewswire.com/news-release/2022/08/02/2490815/0/en/ChemoCentryx-to-Hold-Second-Quarter-2022-Financial-Results-Conference-Call-on-Tuesday-August-9-2022.html?f=22&fvtc=4&fvtv=15166ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 20222022-08-02T20:05:00Z<![CDATA[SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions.]]>https://www.globenewswire.com/news-release/2022/07/05/2474008/0/en/ChemoCentryx-Announces-Appointment-of-Jennifer-L-Herron-to-Board-as-Independent-Director.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director2022-07-05T12:30:00Z<![CDATA[-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- -- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board --]]>https://www.globenewswire.com/news-release/2022/06/06/2456754/0/en/ChemoCentryx-Reports-Safety-Results-Available-from-Ongoing-Phase-I-Trial-of-Orally-Administered-PD-L1-Inhibitor-CCX559-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting2022-06-06T12:30:00Z<![CDATA[-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment ---- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date --]]>https://www.globenewswire.com/news-release/2022/05/31/2453700/0/en/ChemoCentryx-Announces-Abstracts-at-June-Rheumatology-Oncology-and-Nephrology-Conferences.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences2022-05-31T20:05:00Z<![CDATA[SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.]]>https://www.globenewswire.com/news-release/2022/05/31/2453277/0/en/ChemoCentryx-Announces-Changes-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Changes to its Board of Directors2022-05-31T12:30:00Z<![CDATA[-- David E. Wheadon, M.D., Elected to the Board as an Independent Director ---- Henry A. McKinnell, Jr., to Retire from Board --]]>https://www.globenewswire.com/news-release/2022/05/18/2446023/0/en/ChemoCentryx-Announces-Presentation-at-the-Society-for-Investigative-Dermatology-Meeting-Highlighting-the-Role-of-Tunnels-in-Driving-Ongoing-Disease-in-Hidradenitis-Suppurativa.html?f=22&fvtc=4&fvtv=15166ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa2022-05-18T12:30:00Z<![CDATA[-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III --SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunnels in hidradenitis suppurativa, and how these profiles are differentiated with the stage of disease severity. The findings support the Company’s plans to advance TAVNEOS® (avacopan) into Phase III development for the treatment of patients with Hurley Stage III (severe) hidradenitis suppurativa.]]>